Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.

Eur J Clin Pharmacol

Department of Anaesthesiology, Intensive Care, Emergency Care, and Pain Medicine, Turku University Hospital, University of Turku, P.O. Box 52, Kiinamyllynkatu 4-8, FI-20520, Turku, Finland,

Published: March 2015

AI Article Synopsis

  • Tramadol, a pain relief medication, is primarily metabolized into its active form, M1, by the CYP2D6 enzyme, and this study examines how it interacts with antifungal drugs terbinafine and itraconazole.
  • In a study with 12 healthy participants, pretreatment with terbinafine significantly increased tramadol levels while drastically reducing levels of M1, potentially diminishing its pain-relief effectiveness.
  • Itraconazole showed minimal effects on tramadol's metabolism, indicating that it does not significantly alter the drug's efficacy in those with a functional CYP2D6 enzyme.

Article Abstract

Background: Tramadol is widely used for acute, chronic, and neuropathic pain. Its primary active metabolite is O-desmethyltramadol (M1), which is mainly accountable for the μ-opioid receptor-related analgesic effect. Tramadol is metabolized to M1 mainly by cytochrome P450 (CYP)2D6 enzyme and to other metabolites by CYP3A4 and CYP2B6. We investigated the possible interaction of tramadol with the antifungal agents terbinafine (CYP2D6 inhibitor) and itraconazole (CYP3A4 inhibitor).

Methods: We used a randomized placebo-controlled crossover study design with 12 healthy subjects, of which 8 were extensive and 4 were ultrarapid CYP2D6 metabolizers. On the pretreatment day 4 with terbinafine (250 mg once daily), itraconazole (200 mg once daily) or placebo, subjects were given tramadol 50 mg orally. Plasma concentrations of tramadol and M1 were determined over 48 h and some pharmacodynamic effects over 12 h. Pharmacokinetic variables were calculated using standard non-compartmental methods.

Results: Terbinafine increased the area under plasma concentration-time curve (AUC0-∞) of tramadol by 115 % and decreased the AUC0-∞ of M1 by 64 % (P < 0.001). Terbinafine increased the peak concentration (C max) of tramadol by 53 % (P < 0.001) and decreased the C max of M1 by 79 % (P < 0.001). After terbinafine pretreatment the elimination half-life of tramadol and M1 were increased by 48 and 50 %, respectively (P < 0.001). Terbinafine reduced subjective drug effect of tramadol (P < 0.001). Itraconazole had minor effects on tramadol pharmacokinetics.

Conclusions: Terbinafine may reduce the opioid effect of tramadol and increase the risk of its monoaminergic adverse effects. Itraconazole has no meaningful interaction with tramadol in subjects who have functional CYP2D6 enzyme.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00228-014-1799-2DOI Listing

Publication Analysis

Top Keywords

tramadol
7
effects terbinafine
4
terbinafine itraconazole
4
itraconazole pharmacokinetics
4
pharmacokinetics orally
4
orally administered
4
administered tramadol
4
tramadol background
4
background tramadol
4
tramadol acute
4

Similar Publications

Riverbank filtration is a cost-effective and efficient method for drinking water production, using the natural filtration capacity of the river gravelbed. Removal efficiency for organic micropollutants (OMP) in field studies is generally calculated by comparing the concentrations measured in surface water and in the wells either on the same day or with a shift of fixed time interval, neither of which can account for the variability of surface water quality and travel time in the aquifer. The present study proposes a novel method based on travel time distribution determined by a numerical transport model with a hypothesis that it will provide more reliable estimate for OMP removal.

View Article and Find Full Text PDF

Impact of Exercise on Tramadol-Conditioned Place Preference.

Brain Sci

January 2025

Department of Biological Sciences, Faculty of Science, Yarmouk University, Irbid 21163, Jordan.

Background: Tramadol (TRA) is an opioid that is used to manage moderate to severe pain. Long-term use of TRA can lead to the development of opioid use disorder.

Objectives: This study investigates the role of forced exercise in reducing TRA-seeking behavior.

View Article and Find Full Text PDF

Aim: Tramadol (TRM), a widely used opioid analgesic for moderate to severe pain, is associated with liver and kidney toxicity at high doses or prolonged use. This study investigates the protective role of rosmarinic acid (RA), a natural phenolic compound known for its antioxidant, anti-inflammatory, and cell-protective properties, against TRM-induced hepatorenal toxicity.

Methods: Thirty-five male Wistar rats were divided into five groups: Control, TRM, RA, TRM+RA25, and TRM+RA50.

View Article and Find Full Text PDF

Although the dosage controlling of tramadol (TRA) as a banned deadly drug in human biofluids is medicolegally important a biocompatible method for its high-selective detection with fewer false interferences has been scarcely reported. Herein, a new impedimetric aptasensor is introduced by utilizing the aptamer (Apt) sequence with high affinity to TRA for the first time to non-invasively measure it. An oriented nanolayer of Au nanoparticles (AuNPs) is easily formed on the surface by the electrodeposition technique to high-densely load the Apt and embed the novel aptasensing interface via a user-friendly methodology.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!